Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 467 participants.

Also called NCT02833844

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 467 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02833844
  • EudraCT 2015-004735-12
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Brazil, Canada, France, Greece, Italy, Poland, Portugal, Romania, South Africa, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02833844. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-22 (actual); primary completion 2019-07-09 (actual). Results posted on 2020-07-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
Condition
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Intervention (Drug)
Evolocumab
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02833844
Content hash
fac4f080ec256f031d24b6db89adaca7418022c12bf0117c66acee5937277089